Award for leading Spanish ophthalmologist

Article

Dr Jorge Alio, a valued member of Ophthalmology Times Europe?s Editorial Advisory Board, has been acknowledged by The Cornea Research Foundation of America (CRFA) for his technique using Yag laser treatments to eliminate epithelial ingrowth after Lasik.

Dr Jorge Alió, a valued member of Ophthalmology Times Europe’s Editorial Advisory Board, has been acknowledged by The Cornea Research Foundation of America (CRFA) for his technique using Yag laser treatments to eliminate epithelial ingrowth after Lasik.

The Torchbearer Award, presented to Dr Alió, during the ESCRS meeting in Barcelona recognizes individuals whose lifetime service and commitment to the field of vision care has helped light the way for others. It was developed by CRFA Founder Dr Francis W. Price, Jr., MD to recognize dedicated ophthalmic research physicians throughout the world.

The award was made for Dr Alió's work on the development of a non-invasive method to treat glare and halos post laser surgery. According to the CRFA, Epithelial cells rarely grow into the interface between the Lasik flap and underlying stromal bed after primary procedures. However, after re-treatments, where Lasik flaps are lifted and replaced, epithelial ingrowth can occur in up to 5-10% of cases. Dr Alió's innovative treatment creates a dramatic improvement in this condition. Previously flaps had to be re-lifted to remove the cells. The epithelial ingrowth could recur after its removal, and in some cases the Lasik flaps would require suturing down to prevent the epithelial cells from returning. Now with the use of the YAG laser, there are no more flap lifts or sutures to correct this condition providing better outcomes and more comfortable treatments for patients.

To learn more about the Foundation visit www.cornea.org

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.